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Abstract 20 
An ammonium chloride procedure to prepare bacterial pellet from positive blood cultures was 21 
used for direct inoculation of VITEK. Correct identification reached 99% for 22 
Enterobacteriaceae and 74% for staphylococci. For susceptibility testing, very major and 23 
major errors were 0.1% and 0.3% for Enterobacteriaceae, and 0.7% and 0.1% for 24 
staphylococci. 25 
Bacterial pellets prepared with ammonium chloride allow direct inoculation of VITEK cards 26 
with excellent accuracy for Enterobacteriaceae and lower accuracy for staphylococci. 27 
 28 
Main manuscript 29 
Blood cultures are the best approach to establish the etiology of bloodstream infections. 30 
Direct automated identification and antibiotic susceptibility testing (AST) using blood-culture 31 
bacterial pellets were applied for Gram negative bacteria (Bruins et al., 2004; de Cueto et al., 32 
2004; Kerremans et al., 2004) but remains unsatisfactory for the identification of Gram 33 
positive cocci (de Cueto et al., 2004; Kerremans et al., 2004). We developed a simple 34 
procedure to prepare pellets for bacterial identification using MALDI-TOF (Prod'hom et al., 35 
2010). Here, we applied this procedure to directly inoculate VITEK cards (bioMérieux, Marcy 36 
l'Etoile, France) for bacterial identification (ID) and for AST of Gram-positive cocci in cluster 37 
(GPC) and Gram-negative bacteria (GNB) present in blood culture. 38 
During 26 consecutive weeks, all positive blood culture having GNB (1 per patient) or GPC 39 
(1 per site of puncture/per patient) on Gram-stained slides of positive vials were included. 40 
Mixed blood cultures were excluded. Bacterial pellets from positive blood culture vials (Plus 41 
aerobic/F, Lytic anaerobic/F and Peds/F) detected by the automated blood culture system 42 
BACTEC 9240 (Becton Dickinson, Sparks, USA) were prepared with an ammonium 43 
chloride-driven hemolysis (Prod'hom et al., 2010). Briefly, five ml of positive medium was 44 
mixed to 40 ml of sterile water and centrifuged at 1'000xg for 10 min. Supernatant and blood 45 
cells layer were removed. The remaining blood cells were lysed mixing 1 ml of ammonium 46 
chloride (0.15 M NH4Cl, 1 mM KHCO3; pH 7.31) to the bacterial pellet and a second 47 
centrifugation step at 140xg for 10 min was done. Supernatant was discarded. When the pellet 48 
remained hemorrhagic, the lysing step was repeated with 2 ml of water (Prod'hom et al., 49 
2010).  50 
Bacterial pellets (> 108/ml) were used to directly inoculate (McFarland 0.6-0.8) VITEK cards, 51 
GP and AST 580 cards for GPC and GN and GN26 cards for GNB. Positive blood culture vial 52 
were subcultured on blood agar (GPC & GNB) and McConkey agar plates (GNB) to obtain a 53 
pure culture with isolated colonies. ID and AST using the same VITEK cards from colonies 54 
obtained by subculture on agar were used as the gold standard. Quality control of VITEK2 55 
was performed weekly by testing Escherichia coli ATCC 25922 and Staphylococcus aureus 56 
ATCC 29213 for both identification and AST. 57 
For the interpretation of ID results, the following criteria were used i) correct identification 58 
when direct ID and ID from colony gave the same identification, ii) misidentified, when 59 
discordant results were observed between direct ID and ID from colony, iii) not identified 60 
when direct ID gave no identification with the VITEK. 61 
For the interpretation of AST, only cases with correct identification results were analyzed. 62 
VITEK MIC data and interpretation were used for comparison for direct AST and AST from 63 
colonies. Essential agreement (EA), categorical agreement (CA), minor discrepancy (md), 64 
major errors (ME) and very major errors (VME) were used according to definition of 65 
Guidance document of FDA (FDA, 2009). EA was the overall agreement within plus or 66 
minus one two-fold dilution of direct versus colonies inoculation of VITEK cards. CA, the 67 
agreement of interpretive results, susceptible, intermediate, resistant between direct versus 68 
colony inoculation of VITEK cards. AST discordance results were classified as: VME (false 69 
susceptible); ME (false resistant) and md (all others). In case of misidentification, strains were 70 
retested using MALDI-TOF MS directly from colonies. The identification of these isolates by 71 
MALDI-TOF was performed on a Microflex LT instrument (Bruker Daltonics, Leipzig, 72 
Germany) with FlexControl software (version 3.0) (Bizzini et al., 2010). Discrepancies of 73 
AST (VME and ME) were solved by testing isolates using Etest system (BioMérieux). For 74 
each antibiotic Wilcoxon signed rank test were performed to evaluate the MIC values after 75 
log conversion. P value <0.05 were considered significant. 76 
During the study period, 278 positive blood culture where included in the study. Table 1 77 
shows the results of the VITEK identification obtained directly from bacterial pellet compared 78 
to final identification. Overall 226/278 (81%) gave a correct identification at the species level 79 
when VITEK was directly inoculated with bacterial pellets. The proportion of correct 80 
identification for Enterobacteriaceae, non-fermentative GNB, staphylococci and other Gram 81 
positive cocci were of 87/88 (99%), 5/7 (71%), 133/180 (74%) and 1/3 (33%), respectively 82 
(Table 1). Misidentifications were observed for 31/278 (11%) bacterial pellets. For 21/278 83 
(8%) bacterial pellets, VITEK gave no-identification. Noteworthy, all bacterial pellets 84 
identified as S. aureus by the VITEK system were correct. However, as many as 16/77 S. 85 
aureus (21%) were misidentified (Table 1). 86 
Direct AST results from the blood-culture bacterial pellet were analyzed for 220 of the 226 87 
isolates with congruent identification at the species level: 87 Enterobacteriaceae and 133 88 
staphylococci (Table 2). AST GN26 and AST 580 are not appropriate for non-fermentative 89 
bacteria (n=5) and S. pyogenes (n=1). For Enterobacteriaceae, the AST from one case was 90 
excluded since VITEK gave no results due to insufficient growth. For 3 additional cases, 91 
result from 1 antibiotic was excluded since VITEK gave no result. The majority of 92 
discrepancy tests (27/41) confirmed categorical results obtained from colonies. 93 
For the other cases, the EA and CA was overall of 98.5% and 97.7%, respectively. The 94 
number of VME, ME and md were 2 (0.1%), 5 (0.3%) and 30 (1.9%), respectively. For 133 95 
staphylococci, the EA and CA was 96% and 96.2%, respectively. The number of VME, ME 96 
and md were 18 (0.7%), 2 (0.1%) and 76 (3.1%), respectively. The majority of VME was 97 
observed for TMP-SMX (15/18; 83%). 98 
In this study we applied a simple blood pellet procedure using ammonium chloride to 99 
inoculate VITEK cards for both identification and AST. This procedure has several 100 
advantages. First, we do not use additional device such as “serum separator tube” for 101 
preparation of the bacterial pellet (Bruins et al., 2004; de Cueto et al., 2004; Kerremans et al., 102 
2004). Second, the method could be used for both bacterial identification and AST for 103 
Enterobacteriaceae and staphylococci.  104 
For staphylococci AST, very major errors predominate for TMP-SMX. Similar results have 105 
already observed using serum separator tube for bacterial pellet preparation (Kerremans et al., 106 
2004) or saponin as detergent(Lupetti et al., 2010). For staphylococci, the MICs for several 107 
antimicrobial agents was one or more dilutions lower using the direct inoculum method 108 
(P<0.05). 109 
The performance of the direct AST fulfilled performance criteria considered as acceptable by 110 
the FDA administration(FDA, 2009). Thus, we obtained a categorical agreement >90% for all 111 
antibiotics (except fosfomycin (87%) and TMP-SMX (86%) for staphylococci), an essential 112 
agreement >90% for all antibiotics (except teicoplanin (73%) for staphylococci), < 1.5% of 113 
very major errors (0.1% for Enterobacteriaceae, 0.7% for staphylococci) and < 3% of major 114 
errors (0.3% for Enterobacteriaceae, 0.1% for staphylococci). 115 
Two hypothetical factors may explain differences between the tested and the reference 116 
method, i) the presence of residual blood proteins, of blood cells and of blood culture  117 
medium ii) low homogeneity of bacteria in the pellet. The first factors may modify 118 
standardized conditions necessary for identification and AST with VITEK card’s and possibly 119 
may increase the bacterial growth with a significant impact on the biochemical results. The 120 
likely less homogeneous viability of bacteria present in the pellet than that of bacteria 121 
obtained from a subculture may explain altered growth rate and modified MIC’s 122 
determination. Polymicrobial blood cultures may cause errors in antibiotic susceptibility 123 
testing and should be excluded. In most hospitals, the rate of polymicrobial blood cultures is 124 
relatively low (< 10%) allowing the successful application of this method to more than 90% 125 
of all positive blood cultures.    126 
In our hospital, direct identification using VITEK’s cards are used when identification using 127 
MALDI-TOF analysis of bacterial pellet failed. Direct AST on the blood-culture pellet is 128 
applied on both Staphylococci and Enterobacteriaceae. For staphylococci, TMP-SMX result 129 
is not provided to the physician. Implementation of such method in another laboratory may 130 
need an independent validation since the method is an adaptation of CE/FDA approved tool 131 
for off-label purposes. 132 
In conclusion, bacterial pellets from positive blood cultures prepared with an ammonium 133 
chloride-driven hemolysis allow direct inoculation of VITEK cards used for identification and 134 
for antimicrobial susceptibility testing with an excellent accuracy for Enterobacteriaceae and 135 
lower accuracy for staphylococci. To circumvent the lower accuracy of bacterial identification 136 
for staphylococci, we perform a MALDI-TOF identification from bacterial pellet (Prod'hom 137 
et al., 2010). 138 
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Legends 166 
Table 1 : 167 
Direct VITEK identification obtained from bacterial pellet compared to reference VITEK 168 
identification obtained after subcultured colonies. Please not that misidentification were only 169 
observed for Gram positive bacteria 170 
171 
Table 2: 172 
Comparison of MIC’s determined using the VITEK 2 method obtained from direct 173 
inoculation of the blood-culture bacterial pellet with MIC’s determined using the VITEK 2 174 
method obtained from subcultured colonies (reference method) and analysis of categorical 175 
errors. 176 
177 
Table 1 178 
Species Total Correct 
identification 
Misidentified* Not 
identified 
(%)  
Enterobacteriaceae  88 87 (99) 1 
Escherichia coli  50 50 
Klebsiella pneumoniae  16 16 
Enterobacter cloacae  9 8 1 
Klebsiella oxytoca  5 5 
Other Enterobacteriaceae † 8 8 
Non-fermentative Gram-
negative bacteria  
7 5 (71) 2 
P. aeruginosa  4 4 
Other non-fermentative Gram-
negative bacteria ‡ 
3 1 2 
Staphylococci  180 133 (74) 30 17 
S. epidermidis  85 66 10 9 
S. aureus 77 55 16 § 6 
S. hominis  9 5 2 2 
Other staphylococci || 9 7 2 
Other Gram-positive cocci ¶ 3 1 1 1 
Total 278 226 (81) 31 21 
179 
* In case of discordance, identification was confirmed by MALDI-TOF or other reference 180 
methods. 181 
† Serratia marcescens (3), Proteus mirabilis (2), Citrobacter freundii (1), Citrobacter koseri 182 
(1), Enterobacter aerogenes (1). 183 
‡ Achromobacter xylosoxidans (1), Pseudomonas fluorescens (1), Stenotrophomonas 184 
maltophilia (1). 185 
§ S. aureus misidentification: S. intermedius (13), S. chromogenes (1), Streptococcus 186 
pyogenes (1), Kocuria rosae (1). 187 
|| S. capitis (3), S. schleiferi (2), S. auricularis (1), S. lugdunensis (1), S. warneri (1), S. 188 
xylosus (1). 189 
¶ Micrococcus luteus (1), Peptinophilus sp. (1), Streptococcus pyogenes (1)190 
Table 2. 191 
192 
Bacteria/Drugs 
(no. of strains) 
No. of VITEK 2 MICs that differed from  
reference MICs by the indicated dilution * No. of errors after discrepancy analysis † 
 
<-2 -2 -1 0 +1 +2 >+2 EA (%) CA [](%) md [] (%) ME [] (%) VME [] (%) 
Enterobacteriaceae (87 ‡) 
      Amikacin § (86) 
 
1 78 6 1 
 
85 (98.8) 86 (100) 
  Amoxicillin/clavulanate (86) 
 
1 9 70 5 1 84 (97.7) 84 (97.7) 1 (1.2) 1 (1.2) 
Ampicillin (86) 1 
 
5 77 3 85 (98.8) 86 (100) 
 Cefalotin (86) 1 9 68 8 
 
85 (98.8) 79 (91.9) 7 (8.9) 
 Cefepime (86) 1 84 1 85 (98.8) 85 (98.8) 1 (1.2) 
Cefotaxime (85 ‡) 1 84 
 
85 (100) 85 (100) 
 Cefoxitin (86) 
 
3 80 3 
 
86 (100) 85 (98.8) 1 (1.2) 
Cefpodoxime (86) 1 6 77 1 1 
 
84 (97.7) 86 (100) 
 Ceftazidime (86) 
 
85 
  
1 85 (98.8) 85 (98.8) 
 
1 (1.2) 
Cefuroxime (86) 6 74 4 2 84 (97.7) 84 (97.7) 2 (2.4) 
Ciprofloxacin (86) 
 
86 
 
86 (100) 86 (100) 
 Gentamicin (86) 1 84 1 
 
84 (97.7) 85 (98.8) 
 
1 (1.2) 
Meropenem (86) 
  
85 
 
1 85 (98.8) 85 (98.8) 
 
1 (1.2) 
 Nitrofurantoin (86) 1 15 60 10 85 (98.8) 73 (84.9) 12 (16.4) 1 (1.4) 
Norfloxacin (86) 
  
85 1 
 
86 (100) 85 (98.8) 1 (1.2) 
Piperacillin (85 ‡) 
 
2 3 75 4 1 82 (96.5) 83 (97.6) 2 (2.4) 
  Piperacillin/tazobactam (86) 3 2 80 1 80 (93) 81 [80] (94.2) 4 [3] (4.9) 1 (1.2) 0 [2] 
TMP-SMX || (86) 86 
 
86 (100) 86 (100) 
Tobramycin (85 ‡) 
   
84 1 
  
85 (100) 85 (100) 
   Total (1631) 5 8 59 1502 46 5 6 1607 (98.5) 1594 [1593] (97.7) 30 [29] (1.9) 5 (0.3) 2 [4] (0.1) 
Staphylococci (133) 
Clindamycin (133) 1 2 128 1 1 128 (96.2) 129 [128] (97) 4 (3.1) 0 [1] 
Erythromycin § (133) 8 123 1 1 123 (92.5) 131 (98.5) 2 (1.5) 
Fosfomycin § (133) 4 1 128 129 (97) 133 [132] (100) 0 [1] 
Fusidic Acid § (133) 8 16 107 1 1 124 (93.2) 116 (87.2) 17 (14.7) 
Gentamicin (133) 1 7 119 5 1 131 (98.5) 125 (94) 8 (6.4) 
Levofloxacin § (133) 1 32 94 5 1 131 (98.5) 124 (93.2) 9 (7.3) 
Linezolid § (133) 1 26 100 6 132 (99.2) 133 [132] (100) 0 [1] 
Moxifloxacin § (133) 20 112 1 133 (100) 123 (92.5) 10 (8.1) 
Mupirocin (133) 1 132 133 (100) 133 (100) 
Nitrofurantoin § (133) 25 104 4 133 (100) 124 (93.2) 9 (7.3) 
Oxacillin § (133) 4 32 96 1 129 (97) 132 (99.2) 1 (0.8) 
Penicillin (133) 3 5 120 4 1 129 (97) 132 [131] (99.2) 1 (0.8) 0 [1] 
Rifampicin (133) 133 133 (100) 133 (100) 
Teicoplanin § (133) 13 21 23 69 5 1 1 97 (72.9) 127 (95.5) 5 (3.9) 1 (0.8) 
Tetracycline (133) 13 105 13 2 131 (98.5) 129 (97) 4 (3.1) 
Tigecycline (133) 2 11 116 3 1 130 (97.7) 133 (100) 
TMP-SMX § (133) 4 9 15 100 5 120 (90.2) 114 [111] (85.7) 4 (3.5) 0 [2] 
15 [20] 
(13.2) 
Tobramycin § (133) 1 1 8 119 4 131 (98.5) 127 [126] (95.5) 6 (4.7) 0 [1] 
Vancomycin (133) 3 39 54 35 2 128 (96.2) 133 (100) 
Total (2527) 28 59 274 2059 92 11 4 2425 (96) 2431 [2423] (96.2) 76 [72] (3.1) 2 [5] (0.1) 18 [27] (0.7) 
193 
* Differences in MICs (<-2, -2, -1, 0, +1, +2, >+2) indicate log2 differences of VITEK 2 MICs obtained from direct inoculation versus colonies. EA (essential 194 
agreement): no. of MICs concordant with reference VITEK MICs +/- 1 two-fold dilution. 195 
† CA: number of categorical agreement (i.e. susceptible, intermediate, resistant). In bracket [ ]: no. of errors before discrepancy analysis. VME: no. of very 196 
major error (falsely susceptible), ME: no. of major error (falsely resistant), md: no. of minor discrepancies (all other errors). 197 
‡ One inoculum by direct VITEK failed to grow for all antibiotic tested. In 3 cases, VITEK provided an alert for insufficient grow for 1 antibiotics. 198 
§ Significative difference of CMIs using Wilcoxon signed rank test (P<0.05) 199 
|| TMP-SXT: Trimethoprim-sulfamethoxazole 200 
201 
